Background: A corollary of the reserve hypothesis is that what is regarded as pathological cortical metabolism in patients might vary according to education. Objective: The aim of this study is to assess the incremental diagnostic value of education-adjusted over unadjusted thresholds on the diagnostic accuracy of FDG-PET as a biomarker for Alzheimer disease (AD). Methods: We compared cortical metabolism in 90 healthy controls and 181 AD patients from the Alzheimer Disease Neuroimaging Initiative (ADNI) database. The AUC of the ROC curve did not differ significantly between the whole group and the higher-education patients or the lower-education subjects. Results: The threshold of wMetaROI values providing 80% sensitivity was lower in higher-education patients and higher in the lower-education patients, compared to the standard threshold derived over the whole AD collective, without, however, significant changes in sensitivity and specificity. Conclusion: These data show that education, as a proxy of reserve, is not a major confounder in the diagnostic accuracy of FDG-PET in AD and the adoption of education-adjusted thresholds is not required in daily practice.

Keywords:
Reserve, Education, FDG-PET, Alzheimer disease
1.
Katzman R, Terry R, DeTeresa R, et al: Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol 1988; 23: 138–144.
2.
Stern Y: Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord 2006; 20:S69–S74.
3.
Valenzuela MJ: Brain reserve and the prevention of dementia. Curr Opin Psychiatry 2008; 21: 296–302.
4.
Ewers M, Insel PS, Stern Y, Weiner MW: Cognitive reserve associated with FDG-PET in preclinical Alzheimer disease. Neurology 2013; 80: 1194–1201.
5.
Fratiglioni L, Wang HX: Brain reserve hypothesis in dementia. J Alzheimers Dis 2007; 12: 11–22.
6.
Morbelli S, Perneczky R, Drzezga A, et al: Metabolic networks underlying cognitive reserve in prodromal Alzheimer disease: a European Alzheimer disease consortium project. J Nucl Med 2013; 54: 894–902.
7.
Garibotto V, Borroni B, Kalbe E, et al: Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence. Neurology 2008; 71: 1342–1349.
8.
Perani D, Della Rosa PA, Cerami C, et al: Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. Neuroimage Clin 2014; 6: 445–454.
9.
Frisoni GB, Bocchetta M, Chetelat G, et al: Imaging markers for Alzheimer disease: which vs. how. Neurology 2013; 81: 487–500.
10.
Morbelli S, Garibotto V, Van De Giessen E, et al: A Cochrane review on brain [18F]FDG PET in dementia: limitations and future perspectives. Eur J Nucl Med Mol Imaging 2015; 42: 1487–1491.
11.
Garibotto V, Herholz K, Boccardi M, et al: Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol Aging 2017; 52: 183–195.
12.
Landau SM, Harvey D, Madison CM, et al: Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 2011; 32: 1207–1218.
13.
Caroli A, Prestia A, Chen K, et al: Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison. J Nucl Med 2012; 53: 592–600.
14.
Boccardi M, Gallo V, Yasui Y, et al: The biomarker-based diagnosis of Alzheimer’s disease. 2. Lessons from oncology. Neurobiol Aging 2017; 52: 141–152.
15.
Frisoni GB, Boccardi M, Barkhof F, et al: Strategic roadmap for an early diagnosis of Alzheimer’s disease based on biomarkers. Lancet Neurol 2017; 16: 661–676.
16.
Frisoni GB, Perani D, Bastianello S, et al: Biomarkers for the diagnosis of Alzheimer’s disease in clinical practice: an Italian intersocietal roadmap. Neurobiol Aging 2017; 52: 119–131.
17.
Morbelli S, Nobili F: Cognitive reserve and clinical expression of Alzheimer’s disease: evidence and implications for brain PET imaging. Am J Nucl Med Mol Imaging 2014; 4: 239–247.
18.
Perneczky R, Drzezga A, Diehl-Schmid J, et al: Schooling mediates brain reserve in Alzhei-mer’s disease: findings of fluoro-deoxy-glucose-positron emission tomography. J Neurol Neurosurg Psychiatry 2006; 77: 1060–1063.
19.
Foubert-Samier A, Catheline G, Amieva H, et al: Education, occupation, leisure activities, and brain reserve: a population-based study. Neurobiol Aging 2012; 33: 423 e415–e425.
20.
Morbelli S, Brugnolo A, Bossert I, et al: Visual versus semi-quantitative analysis of 18F-FDG-PET in amnestic MCI: an European Alzheimer’s Disease Consortium (EADC) project. J Alzheimers Dis 2015; 44: 815–826.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.